4D Molecular Therapeutics stock maintains Buy rating at Goldman Sachs

Goldman Sachs reiterated its Buy rating and $38 price target for 4D Molecular Therapeutics (FDMT), currently trading at $5.50, following positive clinical developments and strategic financial management. The biopharmaceutical company has initiated North American and global Phase 3 studies for its 4D-150 wet AMD treatment, with topline data anticipated in 2027, and recently announced positive 60-week results from its 4D-150 SPECTRA trial for diabetic macular edema, demonstrating durable activity and a 78% reduction in treatment burden. Additionally, FDMT's strategic workforce reduction is expected to extend its cash runway into 2028, though Goldman Sachs acknowledges ongoing market concerns regarding commercial competition from aflibercept biosimilars.

Analysis

4D Molecular Therapeutics (FDMT) presents a significant valuation disconnect, with Goldman Sachs reiterating a Buy rating and a $38.00 price target while the stock trades at $5.50. This bullish stance is underpinned by substantial clinical progress, notably the initiation of pivotal North American and global Phase 3 trials for its wet AMD treatment, 4D-150, with topline data anticipated in 2027. Confidence in the platform is further bolstered by recent positive 60-week data from the 4D-150 SPECTRA trial for diabetic macular edema (DME), which demonstrated a 78% reduction in treatment burden versus the standard of care. Operationally, the company has extended its cash runway into 2028 through strategic workforce reductions, a prudent move ensuring it is funded through key clinical milestones. However, a key risk acknowledged by the market and Goldman Sachs is the future commercial competition from aflibercept biosimilars, which could impact the ultimate market penetration of FDMT's ophthalmology programs. A minor delay in interim data for the Phase 1 4D-710 cystic fibrosis trial to Q4 2025 is noted but appears to be a logistical adjustment for data maturity rather than a clinical setback.

Key Decisions for Investors

• The substantial gap between the current $5.50 share price and the $38 analyst target from Goldman Sachs may represent a deep value opportunity for investors with a high-risk tolerance and a long-term investment horizon.
• Key catalysts are distant, with pivotal Phase 3 data for the lead asset 4D-150 not expected until 2027, making patience a requisite, though recent positive DME trial results provide a significant de-risking event for the underlying technology.
• Investors should weigh the company's secured cash runway through 2028, which mitigates near-term financing risk, against the acknowledged long-term commercial headwind of biosimilar competition in the ophthalmology space.
• Monitor for any updates on the 4D-710 cystic fibrosis program, as the revised Q4 2025 timeline for interim data serves as a nearer-term milestone and indicator of pipeline execution.